Bayer open for drug licensing deals, cutting debt remains priority

Bayer is ready to spend money on more drug licensing agreements like last year’s deal with Loxo Oncology but its priority is to reduce debt after the takeover of Monsanto.

…read more

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Source:: Reuters – Business News